{"id":41794,"date":"2022-06-08T10:58:42","date_gmt":"2022-06-08T10:58:42","guid":{"rendered":"https:\/\/harchi90.com\/fda-advisory-committee-recommends-novavax-vaccine-for-use-in-adults\/"},"modified":"2022-06-08T10:58:42","modified_gmt":"2022-06-08T10:58:42","slug":"fda-advisory-committee-recommends-novavax-vaccine-for-use-in-adults","status":"publish","type":"post","link":"https:\/\/harchi90.com\/fda-advisory-committee-recommends-novavax-vaccine-for-use-in-adults\/","title":{"rendered":"FDA advisory committee recommends Novavax vaccine for use in adults"},"content":{"rendered":"
\n

The FDA’s vaccine advisory committee voted in favor of Novavax’s (NVAX) COVID-19 vaccine for use in adults, paving the way for the company to get its first product authorized in the US<\/p>\n

But the day-long meeting raised a number of concerns presented by Novavax’s late entry to the vaccine field.<\/p>\n

Before any data was even presented, questions were raised by committee members about the need to authorize yet another COVID-19 vaccine, as demand has waned in the US, and about the manufacturing struggles Novavax – which relied on contract manufacturers\u2014 faced from the start .<\/p>\n

FDA’s Dr. Peter Marks noted that even with three other vaccines available, and with 89% of adults receiving at least one dose, there remained some unmet need. In particular, Marks noted, there are those who are not comfortable with mRNA vaccines, and the Johnson & Johnson (JNJ) vaccine has faced some concerns over associated risks of blood clots.<\/p>\n

\n
\n
\n